

CORRECTION

Open Access

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia



Juanjuan Zhao¹, Yongping Song^{1*} and Delong Liu^{1,2*}

Correction to: *Biomark Res* (2019) 7:19
<https://doi.org/10.1186/s40364-019-0170-2>

The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for 'mitoxantrone, etoposide, cyclophosphamide'.

It should instead be stated that MEC stands for 'mitoxantrone, etoposide, cytarabine'.

Author details

¹Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ²Division of Hematology and Oncology, New York Medical College, Valhalla, USA.

Published online: 17 October 2019

Reference

1. Zhao J, Song Y, Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. *Biomarker Research*. 2019;7:19. <https://doi.org/10.1186/s40364-019-0170-2>.

* Correspondence: songyongping@163.com; DELONG_LIU@NYMC.EDU

¹Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Full list of author information is available at the end of the article

